Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.38 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL919095 | 0.88 | TEAD1 (0.46) | TLR8TEAD1TLR7POLBL3MBTL1 | |
| SCHEMBL921675 | 0.84 | MAPK14 (0.41) | LTA4HKIF11ALDH1A1 | |
| SCHEMBL3110393 | 0.81 | RAB9A (0.37) | TLR8TLR7CYP1A2CYP2C19 | |
| SCHEMBL8155454 | 0.79 | LTA4H (0.43) | LTA4HALDH1A1 | |
| SCHEMBL1283659 | 0.78 | TLR8 (0.41) | TLR8TLR7L3MBTL1IDO1 | |
| SCHEMBL29723532 | 0.77 | LTA4H (0.52) | TLR8TLR7L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL920377 | 0.77 | VEGFA (0.33) | CYP1A2LTA4H | |
| SCHEMBL3110346 | 0.76 | RAB9A (0.34) | TLR8TLR7CYP1A2CYP2C19 | |
| SCHEMBL10993237 | 0.75 | FFAR1 (0.47) | L3MBTL1NPSR1 | |
| SCHEMBL4907828 | 0.75 | RHEB (0.32) | POLBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | TLR8 3740/4885TEAD1 2204/4885TLR7 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.